Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Birtamimab by Prothena Corp for Primary Systemic Amyloidosis: Likelihood of Approval
Birtamimab is under clinical development by Prothena Corp and currently in Phase III for Primary Systemic Amyloidosis. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Prothena Corp's Birtamimab?
Birtamimab is a monoclonal antibody commercialized by Prothena Corp, with a leading Phase III program in Primary Systemic Amyloidosis. According...